St. Jude Medical (STJ) RESPECT Trial for PFO Closure Provides Clinical Evidence of Risk Reduction in Prevention of Recurrent Cryptogenic Stroke
10/25/2012 10:06:02 AM
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a medical device company, today announced results from its RESPECT trial, which studied the AMPLATZER™ PFO Occluder in the prevention of recurrent cryptogenic stroke. Evidence presented at a late breaking trial session during the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, shows that the primary analysis was not statistically significant but trended towards superiority, while additional analyses demonstrated superiority. Stroke risk reduction was observed across the totality of analyses with rates ranging from 46.6 percent - 72.7 percent.